Respiratory distress syndrome – Page 28 – Communicable Diseases Research

COVID-19 in kidney transplant recipients: A multicenter experience in Istanbul

신장 이식 환자의 COVID-19: 이스탄불의 다기관 경험

Multicenter Study

Published on 2020-10-012022-09-11
Journal: Transplant infectious disease : an official journa [Category] MERS, SARS, 진단, 치료제,

The novel coronavirus disease (COVID-19) complicated by pulmonary embolism and acute respiratory distress syndrome

폐색전증과 급성호흡곤란증후군이 복합된 신종 코로나바이러스 감염증(COVID-19)

Case Reports

Published on 2020-10-012022-09-11
Journal: Journal of medical virology [Category] SARS, 바이오마커,

Veno-Arterial-Venous Extracorporeal Membrane Oxygenation in a Critically Ill Patient with Coronavirus Disease 2019

Case Report

Published on 2020-09-302022-10-30
Journal: Medicina [Category] COVID-19, SARS,

[키워드] acute respiratory distress Affect Cardiopulmonary coronavirus disease COVID-19 ECMO Extracorporeal extracorporeal membrane oxygenation Gas exchange Ill IMPROVE lung Respiratory distress syndrome Severe case Support supported syndrome treated
[DOI] 10.3390/medicina56100510 PMC 바로가기 [Article Type] Case Report

Complicated COVID-19 in pregnancy: a case report with severe liver and coagulation dysfunction promptly improved by delivery

Case Report

Published on 2020-09-042022-10-28
Journal: BMC Pregnancy and Childbirth [Category] COVID-19, SARS,

[키워드] abdominal pain acute respiratory syndrome Atypical Caesarean section Case report case sery change Coagulation coagulation dysfunction coagulation impairment coronavirus Course COVID-19 COVID-19 infection differential diagnosis dry cough Evidence exacerbated exaggerate Fever HELLP syndrome high risk immune response Infection liver morbidity Mortality myalgia Nasopharyngeal swab nausea Neonate Obstetric management outcome pandemic Platelet count positive Pregnancy pregnant women raise Respiratory distress syndrome Respiratory failure returned risk SARS-CoV-2 Sepsis Shortness of breath suggested susceptibility the patient Transmission virus was performed women worsened
[DOI] 10.1186/s12884-020-03172-8 PMC 바로가기 [Article Type] Case Report

High dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial

COVID-19에 따른 급성 호흡곤란 증후군에 대한 고용량 덱사메타손 치료: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2020-08-262022-08-13
Journal: Trials [Category] MERS, 임상,

[키워드] 1:1 active cancer acute respiratory distress acute respiratory distress syndrome Adult patients advance directives Advanced cancer age alpha error anticipated approved ARDS assessment assigned bilateral pulmonary infiltrates Blinding block breast-feeding Buenos Aires capture cardiac disease CEMIC clinical clinical trial code Complete concealed Confirmed COVID-19 COVID-19, Dexamethasone, Acute Respiratory Distress Syndrome, Randomised controlled trial, protocol, Steroids delirium develop Dexamethasone diagnosis of SARS-CoV-2 directive discharge disease dissemination do not resuscitate dose Effectiveness element End-Expiratory Pressure evaluate exclusion criteria Expiratory Pressure explained failure followed by Frequency glucocorticoid Glucocorticoids group hemodynamic High dose HIV infection hypoxemic Hypoxemic respiratory failure ICU Immunosuppression Immunosuppressive agents include inclusion criteria Infection Informed consent intensive care unit International legal guardian Length less Life expectancy local Ethics Committee mechanical ventilation Mortality multicenter muscle weakness Nosocomial infection Nosocomial infections number objective open open label open trial other disease other diseases outcome Palliative care PaO parallel group participant Participation Patient Patient care platform Pneumonia Positive end-expiratory pressure power power of 80% Prednisone pressure Prone position protocol R language random randomised randomised controlled trial randomization Randomized randomized clinical trial receive recruitment Registered renal renal disease respiratory respiratory distress Respiratory distress syndrome Respiratory failure resuscitate order RT-PCR Sample size SARS-COV-2 infection SARS-CoV-2 pneumonia secondary Secondary outcomes secondary to sequence Sequential Organ Failure Assessment severe immunosuppression SOFA Standard deviation status Stratified randomization Study protocol subject Support syndrome table terminal Terminal disease title Treatment treatment groups Trial Trial registration two-tailed alpha error Variation ventilator ventilator-free day Ventilator-free days ventilatory Version viral shedding weakness website women
[DOI] 10.1186/s13063-020-04646-y PMC 바로가기 [Article Type] Letter

Extracorporeal Hemoperfusion as a Potential Therapeutic Option for Severe COVID-19 patients; a Narrative Review

Review Article

Published on 2020-08-222022-10-27
Journal: Archives of Academic Emergency Medicine [Category] COVID-19,

[키워드] 2019 novel coronavirus Acute kidney injury acute respiratory syndrome Adult AKI Blood purification caused Complication conditions contribute coronavirus coronavirus disease COVID-19 COVID-19 patient Critically ill CSS Cytokine release syndrome Cytokine storm Cytokine storm syndrome death Deleterious develop epidemiological surveys Extracorporeal Hemoperfusion immune impairment incidence inflammatory mediator Influenza International MERS Middle East multiple organ failure narrative option outbreak outcomes poor prognosis Potential reducing Respiratory distress syndrome Respiratory system review SARS-CoV2 severe COVID-19 Severe infection syndrome the disease therapeutic option treat WHO World Health Organization Wuhan, China
PMC 바로가기 [Article Type] Review Article

Oseltamivir Resistance in Severe Influenza A(H1N1)pdm09 Pneumonia and Acute Respiratory Distress Syndrome: A French Multicenter Observational Cohort Study

Observational Study

Published on 2020-08-142023-06-23
Journal: Clinical Infectious Diseases: An Official Publicat [Category] 신종인플루엔자,

[키워드] Adult H1N1 subtype influenza A virus oseltamivir Pneumonia Respiratory distress syndrome Viral
[DOI] 10.1093/cid/ciz904 [Article Type] Observational Study

Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol

Medicine

Published on 2020-08-042022-10-31
Journal: Frontiers in Medicine [Category] COVID-19,

[키워드] acute respiratory distress administration Adverse ARDS case sery characterized clinical condition Clinical improvement clinical response clinical status clinically Collection complete recovery Course COVID-19 COVID19 Critically ill patient Cytokine storm syndrome death develop disease drug Evidence Evolution help Host hyperinflammation ICU identify immune-mediated diseases Infection inflammation response inhibitor JAK1 JAK2 Laboratory mechanical ventilation modify Mortality non-invasive ventilation organ function Oxygen requirement pandemic PaO Patient primary endpoint progressive COVID-19 progressive disease reduce Research respiratory Respiratory distress syndrome Respiratory function respiratory impairment ruxolitinib ruxolitinib treatment secondary endpoint Serious Adverse Event severe COVID-19 subsequent subset syndrome the disease therapeutic option treat Treatment ventilatory support viral-induced was recorded were assessed with COVID-19
[DOI] 10.3389/fmed.2020.00466 PMC 바로가기 [Article Type] Medicine

A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-07-132022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 24 hour 48 hour Activation acute lung injury acute pneumonia acute respiratory distress syndrome Administered Adult age all-cause mortality Amendment antibodies antibody Antibody test anticipated antiviral therapy approval ARDS assessment assigned baseline Biomarker Blood cardiac disease Care change class Clinical improvement clinical study clinical trial complement Complement inhibitor component Computed tomography concealed Concentration conducted Confirmed Controlled coronary syndrome COVID-19 criteria current Day diagnosis of SARS-CoV-2 dialysis discharge dissemination dose Duration Efficacy element eligibility Endotracheal intubation EU Clinical Trial EudraCT evaluate the effect expected failure female patient Final fraction France Germany greater half-live hospital Hospitalization humanized Hypercoagulable state Immunoglobulin Infection Inflammatory inhibitor initiated intensive care Intubated intubation invasive Invasive mechanical ventilation investigator IVIG Japan Lung injury mechanical ventilation medication monoclonal multicenter Neisseria meningitidis Non-invasive number objective Open-label original outcome oxygen participant Patient patients randomized patients with COVID-19 Period peripheral capillary phase Placebo Pneumonia polymerase chain positive airway pressure presenting progression protocol randomised randomised controlled trial randomization randomization list Randomized randomized controlled study Randomly Ravulizumab receive recruitment registry Remdesivir renal respiratory respiratory distress Respiratory distress syndrome routine clinical care Safety screened Screening secondary Serious Adverse Events serum severe acute respiratory distress syndrome coronavirus 2 Severe acute respiratory syndrome severe COVID-19 severe pneumonia SOFA Spain SpO2 Sponsor stratified Study protocol supportive care survival The United States therapy time Treatment treatment-emergent adverse event Ultomiris United Kingdom ventricular Viral website with COVID-19 X-ray
[DOI] 10.1186/s13063-020-04548-z PMC 바로가기 [Article Type] Letter

COVID-19 and hypertension-evidence and practical management: Guidance from the HOPE Asia Network

코로나19와 고혈압 근거와 실천: HOPE Asia Network의 안내

Review

Published on 2020-07-012022-09-11
Journal: Journal of clinical hypertension (Greenwich, Conn. [Category] SARS, 바이오마커,

[키워드] acute respiratory distress acute respiratory distress syndrome addition adverse outcome adverse outcomes age angiotensin Angiotensin receptor blockers Angiotensin-converting enzyme angiotensin-converting enzyme 2 angiotensin-converting enzyme 2 receptors angiotensin-converting enzyme inhibitors antihypertensive therapy Asia best Biomarker Biomarkers blood pressure can be used cardiac injury cells Complication coronavirus coronavirus 2019 disease Course COVID-19 creatinine cytokine Cytokine storm D-dimer develop Evidence facilitate Factor Health status heart failure help home blood pressure monitoring hypertension include increase independent independent of Infection inhibitor Kidney injury maintain maintenance management MONITOR myocardial injury N-terminal N-terminal pro-B-type natriuretic peptide network new infection Other outcome pandemic Patient Patient management patients patients with COVID-19 peptide poor prognosis pro-B-type natriuretic peptide Psychological well-being RAS RAS inhibitor RAS inhibitors receptor regular exercise Renin renin-angiotensin system respiratory distress Respiratory distress syndrome resulting risk risk factor Risk factors risk stratification SARS-CoV-2 virus SARS-CoV-2 virus infection serum creatinine severe COVID-19 social distancing syndrome Telemedicine the SARS-CoV-2 virus thrombosis troponin virus infection
[DOI] 10.1111/jch.13917 PMC 바로가기 [Article Type] Review